Plain-English translation of NCT07303907 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a small research study testing DT402, a medication that works by changing levels of natural brain chemicals involved in mood and communication. The study will enroll about 20 adults with autism spectrum disorder to see how the medication affects their symptoms. Researchers are especially interested in whether this treatment might help improve social skills and communication.
Current treatments for autism don't fully address the social and communication challenges that many people experience. This study is exploring whether this medication, which affects brain chemistry in a specific way, could offer a new option for adults struggling with these core autism-related difficulties.
You likely qualify if…
You likely don't qualify if…
You would visit the research center for a single study visit where you would receive one dose of the medication by mouth. Researchers would then observe and measure your responses, likely using standardized tests to assess changes in social responsiveness and communication. The exact duration of the visit and follow-up period would be detailed when you speak with the research team.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
United States
Testing effectiveness
Sponsor
Definium Therapeutics US, Inc.
Enrollment target
~20 participants
Started
December 2025
Primary completion
August 2027
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Definium Therapeutics Clinical Trials Information Requests
Definium Therapeutics US, Inc.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.